Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
14.66
+0.24 (1.66%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$2,363,785
Market Cap
2.21B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| AbCellera Biologics | 562 |
| Vericel | 398 |
| Nuvation Bio | 307 |
| UroGen Pharma | 298 |
| Harmony Biosciences Holdings | 293 |
| Stoke Therapeutics | 170 |
| Aurinia Pharmaceuticals | 128 |
BHVN News
- 3 days ago - Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - PRNewsWire
- 13 days ago - Biohaven and Yale University awarded $4M in trade secret verdict - TheFly
- 13 days ago - Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - PRNewsWire
- 20 days ago - Biohaven reports new data on BHV-1530 - TheFly
- 20 days ago - Biohaven enters into clinical supply agreement with Regeneron - TheFly
- 20 days ago - Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - PRNewsWire
- 4 weeks ago - Biohaven’s Bruce Car retires as chief scientific officer - TheFly
- 4 weeks ago - Biohaven Announces Scientific Leadership Transitions - PRNewsWire